Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

September 4, 2027

Study Completion Date

February 4, 2030

Conditions
Resectable Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Capecitabine

Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.

DEVICE

Selective Internal Radiotherapy (SIRT)

During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.

PROCEDURE

Surgery

Surgery will be performed according to local practice.

Trial Locations (7)

33604

RECRUITING

Groupe SUD-Haut-Lévêque - Centre Hospitalier Universitaire de Bordeaux, Pessac

34295

ACTIVE_NOT_RECRUITING

Centre Hospitalier Universitaire de Montpellier, Montpellier

35042

RECRUITING

Centre de Lutte contre le Cancer Eugène Marquis, Rennes

86021

ACTIVE_NOT_RECRUITING

Centre Hospitalier Universitaire de Poitiers, Poitiers

92118

RECRUITING

Hôpital Beaujon, Clichy

94000

ACTIVE_NOT_RECRUITING

Hôpital Henri - Mondor, Créteil

94805

RECRUITING

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Center Eugene Marquis

OTHER